Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Volume: 378, Issue: 22, Pages: 2078 - 2092
Published: Apr 16, 2018
Abstract
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer...
Paper Details
Title
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Published Date
Apr 16, 2018
Volume
378
Issue
22
Pages
2078 - 2092
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.